PROFESSIONAL COMPOUNDING CENTERS OF AMERICA (PCCA) (50% INTEREST);BEST PET RX IP, INC. (50% INTEREST)
发明人:
Chris V. Simmons,Danny Carrero
申请号：
US15210632
公开号：
US09895446B2
申请日:
2016.07.14
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Intralesional injections including poloxamer compounds and anticancer drugs are disclosed. The combination of the poloxamer-based composition with chemotherapeutic agents within the disclosed intralesional injections provides a synergistic effect, thereby allowing lower dosages of the active drugs and enhancing the treatment effectiveness. The disclosed poloxamer-based intralesional injections are employed for treating different types of cancer in humans and other animal species. The disclosed intralesional injections can be used as the sole therapy or in combination with one or more additional therapies, such as, chemotherapy, electrotherapy, immunotherapy and/or radiation therapy. The disclosed intralesional injections can be employed in virotherapy and gene therapy treatments. The disclosed intralesional injections are designed for immediate release or controlled release of the active drugs. The disclosed intralesional injections are employed for local or systemic administration of active drugs.
